There will only be 40 people world-wide (US, Europe and New Zealand) in this study you you have HVC, cirrhosis, HCC and awaiting transplant within the next 6 months this may be the best way to cure yourself of hepatitis C for good. Two oral drugs NO interferon. GS-7977 + Ribavirin. Currently recruiting.
"An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant"
This study is currently recruiting participants.
Verified April 2012 by Gilead Sciences
Study NCT01559844 Information provided by Gilead Sciences
http://clinicaltrials.gov/ct2/show/NCT01559844?term=gilead+gs-7977&rank=4
Current Primary Outcome Measures - To determine if the administration of a combination of GS 7977 and ribavirin to HCV-infected subjects with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior to undergoing liver transplantation for up to 24 weeks can prevent post-transplant re-infection as determined by a sustained post-transplant virological response (HCV RNA 10e4 IU/mL at Screening
Patients meeting the MILAN criteria undergoing liver transplant for HCC secondary to HCV with a MELD of 10 mg/day) in the Pre-transplant treatment period.
History of previous solid organ transplantation
Evidence of renal impairment (CrCl < 60 mL/min) calculated by the Cockroft-Gault equation.
History or current evidence of psychiatric illness, immunologic disorder, hemoglobinopathy, pulmonary or cardiac disease, porphyria, or poorly controlled diabetes, cancer other than HCC, or a history of malignancy that in the opinion of the investigator makes the patient unsuitable for the study. Patients with clinical signs or symptoms of acute pancreatitis with elevated lipase (at Screening or during the Screening period)
Known hypersensitivity to RBV, the study investigational medicinal product, the metabolites, or formulation excipients.
History of having received any systemic antineoplastic (including sorafenib) or immunomodulatory treatment (including radiation) within 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study (excluding a local regional therapy such as TACE).
Treatment with Transcatheter arterial chemoembolization (TACE) or radio frequency ablation (RFA) within 30 days prior to the first dose.
Participation in a clinical study with an investigational drug, biologic, or device within 3 months prior to first dose administration at the Baseline/Day 1 Visit.
Cheers!
Hector